I appreciate that, Mr. Chair, and all the presentations.
I'm particularly interested in what I guess is a bit of a running theme, and that is the issue of whether our investment in our current research in potential breakthrough drugs—new drugs for new and sometimes rare diseases, as well, and others—is actually benefiting Canadians. In other words, in terms of the disconnect that I'm hearing or perceiving from some of our witnesses, previously and today, between the drugs that are recommended for approval by the CDR and the people accessing those drugs, and the money that's being put into the investment and the research to ensure that we have these new, innovative drugs available, do you believe that there is a disconnect? That's something that I am picking up.